Is now a good time to buy INFE.PA stock for a short-term bounce?

For a short-term oversold bounce, INFE.PA stock looks attractive given the pullback to **€71.00** and a 50-day gap. Use small sizes and tight stops due to low volume. Confirm with intraday volume before adding positions.

What are the main valuation metrics for INFE.PA stock?

Key metrics: **EPS €6.35**, **PE 11.18**, cash per share **€29.94**, price-to-sales **0.33**, EV/EBITDA **1.96**. These indicate a value-oriented profile versus Industrials peers.

What price targets should investors watch for INFE.PA stock?

Meyka AI's 1-year forecast is **€74.29** (implied +4.63%). Tactical targets: conservative **€75.00**, stretch **€80.00**, longer-term models show **€83.65** to **€93.19**.

How does liquidity affect trading INFE.PA stock?

Liquidity is thin: current volume **16** vs avg **85**. Thin liquidity can magnify price swings and widen spreads. Use limit orders and keep position sizes small to manage execution risk.

EU Stocks

INFE.PA Compagnie Industrielle EURONEXT Pre-Market 21 Feb 2026: €71.00 pullback sets oversold bounce

ByDanny Kontos February 21, 2026February 21, 2026

We see INFE.PA stock trading at €71.00 pre-market on EURONEXT as of 21 Feb 2026 after a short-term pullback from the 50-day average. The move leaves a possible oversold bounce setup given the 3-month decline of -14.46% but a 6-month gain of +26.79%. Key fundamentals remain solid: EPS €6.35 and PE 11.18. Volume is light at 16 shares versus a 50-day average of 85, so price swings may amplify. As an AI-powered market analysis platform, Meyka AI flags a tactical rebound opportunity while noting liquidity and dividend data that need verification.